Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury
نویسندگان
چکیده
منابع مشابه
Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
BACKGROUND Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are becoming increasingly important and can help...
متن کاملAdvances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma.
Although the majority of patients with Hodgkin lymphoma attain a complete response with initial combination chemotherapy and/or radiotherapy, 20–40% of patients with newly diagnosed, advanced-stage Hodgkin lymphoma are refractory to initial therapy or relapse following a response.1,2 The optimal second-line treatment approach for these patients is high-dose chemotherapy followed by autologous s...
متن کاملBrentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after...
متن کاملBrentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
Up to 40% of patients with advanced Hodgkin lymphoma (HL) become refractory or relapsed after current standard chemotherapy, among which primary refractory HL confers a particularly poor outcome. With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission rate for these patients was only 30%, but more selective treatments with higher therapeutic index a...
متن کاملComplete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
644.8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lympho-cyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by theGerman Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111.9. Advani RH, Horning SJ, Hoppe RT, et al. Frontline therapy of nodularlymphocyte predominant Hodgkin lymphoma with rituximab: the StanfordUniversi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2019
ISSN: 2072-6694
DOI: 10.3390/cancers11111687